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ABSTRACT 
Objective: The proposed study is focussed at developing acyclovir microsponges for oral drug delivery systems.  QbD was applied for better 
understanding of the process and to generate design space, using quality target product profile, critical quality attributes, and risk assessment. 
The aim of the experiment is to prepare a safe, efficacious, stable and patient compliant microsponge dosage form of Acyclovir. Materials and 
methods: Pre-formulation studies were carried out which helped in developing a suitable dosage form. UV, FTIR, DSC, and SEM studies were 
done for pre-formulation and post-formulation evaluations. QbD was applied to generate design space, using QTPP, CQA, and risk assessment. 
Microsponges of acyclovir were developed by 23 factorial designs. Three variables Drug: Polymer ratio (X1), Concentration of surfactant (X2) and 
Stirring speed (RPM) (X3) at two levels low and high were selected and response surface plots were generated. The microsponges were prepared 
by Quassi-emulsion solvent diffusion method. Various characterizations that were carried out include entrapment efficiency, percentage yield, 
particle size determination, in-vitro drug release studies and kinetic modelling of drug release. Statistical analyses of batches and surface 
response studies were done to understand the effect of various independent variables on the dependent variables. Results and Discussions: 
The λmax was confirmed at 251 nm by UV spectroscopy. The melting point was determined experimentally to be 2460C which confirms the drug 
to be Acyclovir. FTIR and DSC studies confirmed that the drug is Acyclovir. Eight trials were taken as per the by 23 factorial designs.  Conclusion: 
The study indicates that microsponges of Acyclovir by QbD approach were successfully developed.  
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INTRODUCTION 
Acyclovir is a potent, specific antiviral drug which is active 
against herpes simplex viruses’ types I and II and varicella 
zoster virus1. Literature studies indicate that the oral 
bioavailability of acyclovir is relatively less, which is around 
20-30%. Hence there is a need for enhancement of oral 
bioavailability of the acyclovir drug by employing various 
approaches. Acyclovir is available as various dosage forms in 
the market which includes capsules, creams, ointments, 
tablets and suspension. For all oral dosage forms the limiting 
factor of bioavailability which is poor. In order to overcome 
this limitation of oral delivery of Acyclovir, attempts have to 
be made to develop novel drug delivery systems of the same 
drug. The underlying aim of the proposed investigation is to 
augment the oral bioavailability of acyclovir by developing a 
microsponge drug delivery system of acyclovir which will 
attempt to increase the oral bioavailability of the drug. 
Microsponges are spherical small structures having large 
void spaces where there can be entrapment of the drug. 
These voids are non-collapsible; hence it is better for drug 
entrapment and the entrapment efficiency of microsponges 
would be very high. The release of the drugs from the 
microsponges involves the movement of the drug from these 
non-collapsible void spaces to outside. The presence of such 
void spaces may enable the micrsoponges to deliver the drug 
slowly over a period for prolonged time2. As such drug 
delivery systems are devoid of much irritation and are 
capable of prolonged activity; they can enhance the patient 
compliance. Quality by design (QbD) is an intelligent way to 
bring quality into both product and process. QbD can be 
achieved by constructive planning of all the previous data 
that is accessible. Although it is based on certain amount of 
risks, it provides results that minimizes the risk of end 
product failure and enhances the chances of regulatory 
acceptance3. ICH Q8, ICH Q9 and ICH Q10 do explain the 
principles of QbD in the best way. They provide guidelines on 
science and risk based assessment, life cycle of product and 
various approaches in its development. It is also well known 
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fact that there can be a great deal of unpredictability in scale 
up of a product from research and development, although 
the reason for failure is not generally understood. QbD is an 
approach to be applied in all stages of drug discovery, 
production and delivery4-6. 
MATERIALS AND METHODS 
Materials  
The drug Acyclovir was obtained as gift sample from 
Aurobindo Pharma, Hyderabad. All other chemicals that 
were used in the experiment were of the analytical grade.  
Methods 
Pre-formulation studies 
Determination of melting point of Acyclovir: 
Melting point of Acyclovir was determined by open capillary 
method.  
Determination of wavelength maxima (λmax) of Acyclovir: 
Determination of wavelength maxima (λmax) was done for 
Acyclovir. 
Preparation of calibration curve for Acyclovir: 
The calibration curve of Acyclovir was plotted by taking 0.1N 
HCl as the solvent.  
Identification of Acyclovir by FT-IR Spectroscopy: 
FTIR study was carried for Acyclovir.  
Identification of Acyclovir by DSC Study:  
The thermograph of Acyclovir was obtained by DSC.  
Method of preparation of Acyclovir microsponges: 
Microsponges are prepared by quasi-emulsion solvent 
diffusion technique. In this method external phase and 
internal phases are used. The internal phase is organic phase 
was containing drug (acyclovir), Dichloromethane, Eudragit 
RS100 and triethyl citrate (TEC) which is added in order to 
facilitate the plasticity. The external phase consisted of 
distilled water and polyvinyl alcohol (PVA) which acts as 
surfactant. Measured amounts of drug and polymer are 
dissolved in measured quantity of DCM. The formed solution 
is poured into water containing polyvinyl alcohol. Internal 
phase and external phases were properly mixed. This results 
in the solidification of the drug and its diffusion out of the 
liquid phases. Finally the solidified microsponges are 
collected by filtration. Then they are subjected to washing 
and drying. 
Characterization of Acyclovir microsponges: 
Entrapment efficiency: 
Drug Encapsulation efficiency = 
                 
                      
     
Percentage yield: 
Percentage Yield=
                             
                     
     
Drug content: 
Drug content is determined by using the UV Visible 
spectrophotometer.  
Average particle size analysis: 
Malvern apparatus was used for particle size analysis. 
In-vitro drug release study of microsponges: 
Dissolution test was carried out to determine the in-vitro 
drug release profile of the prepared batches of 
microsponges.  
Kinetics of drug release: 
Kinetic release study was performed to find drug release 
mechanism from dissolution parameter by using different 
various kinetic model equations like Zero order, First order, 
Higuchi, Hixon-Crowell and Korsemeyer-Peppas model. 
Risk Assessment to identify CQAs affecting drug product 
quality: 
Risk assessments was done to select formulation and process 
variable which may affect product quality for CQAs by 
process characterization that defines satisfactory changes in 
material and process parameters. As a final point, this can 
result in quality assurance by process design space to 
understand and develop control strategy. Critical quality 
attributes were categorized into high, medium and low risk 
parameters based on knowledge space. Usually high-risk 
parameters are considered important for Design of 
Experiments as they are having more effect than others and 
need to be in accepting multivariate ranges.  
 
Figure 1 QbD approach 
 
Table 1 Independent and dependent variables 
 Independent variables – X Dependent 
Variables – Y 
Polymer Type and Concentration Particle Size 
Drug: Polymer Ratio 
Internal Phase Type Entrapment 
Efficiency (%) Internal Phase Volume 
External Phase Volume Drug content 
Surfactant Type and Its 
Concentration 
Stirring Speed and Time % Cumulative 
Drug Release  
 
Effect of different independent variables were checked by 
evaluating particle size, entrapment efficiency (%), particle 
size and % cumulative drug release of Acyclovir 
microsponges formulated in preliminary trial batches. Based 
on that characterization, CQAs were selected which have 
greater effect on microsponges formulations. 
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Design of Experimentation (DoE) of Acyclovir 
microsponges by using QbD approach: 
A design space can signify formulation and process variables 
that affects attributes which are related to drug substance, 
materials, equipments and finished product quality. For this 
purpose, risk assessment was done based on understanding 
of process and formulation related parameters on 
microsponges’ quality. Preliminary studies and later Design 
of Experimentation (DoE) was carried out for high risk 
parameters. Based on effect of critical quality attributes of 
target product profile, design space for obtaining robust 
formulation was proposed.  
RESULTS AND DISCUSSIONS 
Pre-formulation studies 
Determination of melting point of Acyclovir: 
The melting point of Acyclovir was found to be 256.5 °C  
Determination of wavelength maxima (λmax) of Acyclovir: 
The wavelength maxima (λmax) of Acyclovir were found to be 
251 nm. 
  
 
Figure 2 Wavelength max (λmax) of Acyclovir 
 
Preparation of calibration curve for Acyclovir: 
 
Figure 3 Calibration curve for Acyclovir 
Identification of Acyclovir by FT-IR Spectroscopy: 
The recorded IR spectrum of Acyclovir is shown in following figure. 
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Figure 4 FTIR spectrum of Acyclovir 
Table 2 FT-IR peaks of Acyclovir 
Type of Vibration Standard Wave number(cm-1) Observed Wave number(cm-1) 
C=C Stretching of Aromatic 1600-1475 1465.90 
 -   tretching of     amine 3500-3300 3417.88 
N-O Stretching of N - Oxide 1300-1200 1222.87 
C-H Stretching of Piperidines 2850-3000 2937.59 
C-N Stretching of C-NH2 860-766 761.88 
 
Identification of Acyclovir by DSC Study: 
 
Figure 5: DSC thermograph 
 
23 Factorial Design for Acyclovir microsponges 
Various batches of Acyclovir microsponges by DoE Using 
QbD approach were prepared according to 23 factorial 
designs which are as shown in Table 3. 
Compositions of Factorial Batches in Coded Form 
Various batches of Acyclovir microsponges with Eudragit RS 
100 were prepared according to 23 factorial designs which 
are as shown in Table 4. 
 
Table 3: 23 Factorial Design 
Independent Variables Low (-) High (+) 
Drug: Polymer ratio (X1) 1:1 2:1 
Concentration of surfactant (X2) 0.75% 1% 
Stirring speed (RPM) (X3) 1500 2000 
Dependent Variables 
Y1 = % Yield 
Y2 = % Entrapment efficiency 
Y3 = Particle Size 
Y4 =% CDR 
 
Table 4: Compositions of Factorial Batches in Coded Form 
23 =8 Batches 
 
Batch  
No. 
Variable level in coded form 
Drug: Polymer Ratio 
(X1) 
Concentration of surfactant 
(X2) 
Stirring speed (RPM)  
(X3) 
1 -1 -1 -1 
2 +1 -1 -1 
3 -1 +1 -1 
4 +1 +1 -1 
5 -1 -1 +1 
6 +1 -1 +1 
7 -1 +1 +1 
8 +1 +1 +1 
Temp Cel
250.0200.0150.0100.050.0
DSC
 mW
10.00
0.00
-10.00
-20.00
-30.00
-40.00
-50.00
DDS
C m
W/m
in
154.2Cel
-16.92mW
253.7Cel
-38.87mW
ACYCLOVIR
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Formulation Design by 23 Factorial Design 
Table 5: Formulation Design by 23 Factorial Designs 
Batch Drug: Polymer Ratio 
(X1) 
Concentration of surfactant 
(X2) 
Stirring speed (RPM)  
(X3) 
ACVMS1 1:1 0.75 1500 
ACVMS2 2:1 0.75 1500 
ACVMS3 1:1 1 1500 
ACVMS4 2:1 1 1500 
ACVMS5 1:1 0.75 2000 
ACVMS6 2:1 0.75 2000 
ACVMS7 1:1 1 2000 
ACVMS8 2:1 1 2000 
 
Characterization of Acyclovir microsponges: 
Table 6 Characterization of Batches ACVMS1- ACVMS8 
Batch No Yield-% (Y1) 
(Mean ± S.D.) 
(n = 3) 
E.E.-% (Y2) 
(Mean ± S.D.) 
(n = 3) 
P. Size-μm (Y3) 
(Mean ± S.D.) 
(n = 3) 
Drug Content (Y4) 
(Mean ± S.D.) 
(n = 3) 
ACVMS1 71.45±1.15 86.25±1.82 19.42±2.54 82.66±1.55 
ACVMS2 75.52±1.66 87.28±1.97 26.46±2.76 80.46±1.20 
ACVMS3 72.48±1.85 88.56±1.54 17.25±1.18 85.38±2.33 
ACVMS4 81.49±2.24 92.28±1.77 15.23±1.87 88.57±1.44 
ACVMS5 67.38±1.52 86.66±1.65 18.29±1.60 81.39±1.56 
ACVMS6 77.13±1.38 93.14±1.44 7.4±1.74 87.63±1.75 
ACVMS7 84.18±2.28 88.19±1.89 17.22±1.67 83.82±2.65 
ACVMS8 86.17±1.49 90.52±2.73 21.51±2.23 86.32±1.78 
 
 
Figure 6: Characterization of Batches ACVMS1 – ACVMS8 
% Cumulative Drug Release profile of batches ACVMS1- ACVMS8 
Table 7: % Cumulative Drug Release profile of Batches ACVMS1 – ACVMS4 
 
Time 
ACVMS1 
(Mean ± SD) 
(n=3) 
ACVMS2 
(Mean ± SD) 
(n=3) 
ACVMS3 
(Mean ± SD) 
(n=3) 
ACVMS4 
(Mean ± SD) 
(n=3) 
0 0 0 0 0 
1 28.01±1.13 14.18±1.78 15.16±1.45 21.25±1.49 
2 37.81±1.74 18.21±1.46 17.30±1.17 27.81±1.65 
3 44.95±1.56 26.84±1.29 22.85±1.59 36.38±1.37 
4 56.25±1.93 32.59±1.66 31.37±1.17 46.90±1.58 
5 63.45±1.63 43.20±1.52 42.61±1.79 51.48±1.48 
6 76.11±1.28 54.01±1.68 53.33±1.62 66.37±1.75 
7 85.26±1.82 65.01±1.84 66.08±1.28 81.42±1.81 
8 90.32±1.25 78.06±1.94 75.91±1.56 88.96±1.26 
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Figure 7:% Cumulative Drug Release profile of Batches ACVMS1 – ACVMS4 
Table 8: % Cumulative Drug Release profile of Batches ACVMS5 – ACVMS8 
 
Time 
ACVMS5 
(Mean ± SD) 
(n=3) 
ACVMS6 
(Mean ± SD) 
(n=3) 
ACVMS7 
(Mean ± SD) 
(n=3) 
ACVMS8 
(Mean ± SD) 
(n=3) 
0 0 0 0 0 
1 16.33±1.17   28.01±1.87 21.73±1.54 17.88±1.93 
2 21.44±1.67 37.84±1.64 30.35±1.71 26.45±1.56 
3 31.76±1.65 44.95±1.92 46.31±1.95 36.97±1.76 
4 40.67±1.39 56.25±1.66 56.34±1.62 38.72±1.82 
5 51.18±1.36   63.45±1.25 61.80±1.48 60.95±1.19 
6 61.48±1.82 76.11±1.86 71.82±1.26 73.38±1.17 
7 74.94±1.28 85.26±1.48 84.87±1.82 84.87±1.42 
8 85.55±1.52 90.32±1.49 93.24±1.65 91.74±1.62 
 
 
Figure 8: Cumulative Drug Release profile of Batches ACVMS5 – ACVMS8 
Table 9: Release Kinetic of BatchesACVMS1 – ACVMS4 
Model Parameter ACVMS1 ACVMS2 ACVMS3 ACVMS4 
Zero Order R2 0.9468 0.9829 0.9609 0.9733 
Slope 10.299 8.4804 8.2129 10.202 
Intercept 11.45 2.4204 2.0214 5.7064 
First Order R2 0.9688 0.9654 0.9338 0.9673 
Slope -0.0956 -0.0532 -0.0513 -0.073 
Intercept 1.9886 2.0048 2.0067 1.9988 
Higuchi Model R2 0.9856 0.9899 0.9859 0.9865 
Slope 30.03 21.123 20.267 25.136 
Intercept - 1.8141 - 4.825 - 4.7016 - 6.3716 
Hixon Crowell R2 0.9757 0.9752 0.9462 0.9775 
Slope 0.2699 0.1669 0.1611 0.2183 
Intercept 0.0997 0.0055 - 0.0014 0.042 
Korsmeyerpe
ppas equation 
R2 0.8786 0.8938 0.8432 0.9089 
Slope 74.833 54.858 52.188 66.878 
Intercept 14.108 5.4689 5.3575 9.0138 
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Table 10: Release Kinetic of BatchesACVMS5 – ACVMS8 
Model Parameter ACVMS5 ACVMS6 ACVMS7 ACVMS8 
Zero 
Order 
R2 0.9867 0.9467 0.97 0.9679 
Slope 10.049 11.451 11.735 11.413 
Intercept 2.1189 10.306 6.5582 2.8125 
First 
Order 
R2 0.964 0.9688 0.9935 0.9103 
Slope -0.0687 -0.0956 -0.0915 -0.0889 
Intercept 2.0155 1.9886 2.0019 2.03 
Higuchi 
Model 
R2 0.9968 0.9856 0.9938 0.9827 
Slope 24.896 30.029 30.221 28.326 
Intercept - 6.2585 - 1.8083 - 5.0004 - 6.7818 
Hixon 
Crowell 
R2 0.9767 0.9757 0.9934 0.9386 
Slope 0.2089 0.2699 0.2651 0.2573 
Intercept - 0.0177 0.0999 0.0439 - 0.0387 
Korsmeye
rpeppas 
equation 
R2 0.899 0.8785 0.9429 0.8798 
Slope 65.068 74.827 78.487 73.807 
Intercept 5.7057 14.115 9.7267 6.9227 
 
 
Statistical analysis of batches ACVMS1- ACVMS8  
In factorial design, amount of drug (ACV): polymer (Eudragit 
RS100) ratio (X1), amount of PVA Concentration (X2), and 
Stirring Speed (X3) were taken as independent variables. % 
Yield (Y1), % E. E (Y2). Particle sizes (Y3), % CDR (Y4) were 
selected as dependent variables. 
Effect on % Yield (Y1) - Surface Response Study 
Y1 (%Yield) = 77.73 + 5.52*X1 + 1.44 *X2 – 2.86*X3 
Positive value for coefficient of X1 in equation indicates 
Increase in yield with Drug Concentration. Positive value of 
coefficient of X2 PVA concentration indicates increase in 
response of Y1 i.e. % yield. Negative value of coefficient X3, 
time indicates decrease in yield. 
Effect on % Entrapment Efficiency (Y2) - Surface 
Response Study 
Entrapment Efficiency (Y2) = 
 84.75 + 0.875 * X1 + 0.55 * X2 + 1.05 * X3 
Positive value for coefficient of X1 in equation indicates 
increase in Entrapment Efficiency with Drug Concentration. 
Positive value of coefficient of X2 PVA concentration 
indicates increase in response of Y2 i.e. % E.E. Positive value 
of coefficient X3, time indicates increase in yield.  
Effect on Particle Size (Y3) - Surface Response Study 
P.S. (Y3) = 18.85 – 2.51 * X1 + 2.26 * X2 – 3.31 * X3 
Negative value for coefficient of X1 in equation indicates 
decrease in particle Size with Drug Concentration. Positive 
value of coefficient of X2 PVA concentration indicates 
increase in response of Y3 i.e. P.S. Negative value of 
coefficient X3, time indicates decrease in Particle size. 
Effect on % CDR (Y4) - Surface Response Study 
%CDR (Y4) = 87.03 + 4.54 * X1 - 2.86 * X2 – 0.84 * X3  
Positive value for coefficient of X1 in equation indicates 
Increase in CDR with Drug Concentration. Negative value of 
coefficient of X2 PVA concentration indicates decrease in 
response of Y4 i.e. % CDR. Negative value of coefficient X3, 
time indicates decrease in CDR.  
CONCLUSION 
The focus of the current study was to develop microsponge 
drug delivery system of acyclovir using QbD approach. . 
Literature studies indicate that the oral bioavailability of 
acyclovir is relatively less, which is around 20-30%. The 
underlying objective of the proposed investigation is to 
augment the oral bioavailability of acyclovir by developing a 
microsponge drug delivery system of acyclovir. Pre-
formulation studies were carried out which helped in 
developing a suitable dosage form. UV, FTIR, DSC, and SEM 
studies were done for pre-formulation and post-formulation 
evaluations. QbD was applied to generate design space, using 
QTPP, CQA, and risk assessment. Microsponges of acyclovir 
were developed by 23 factorial designs. Three variables 
Drug: Polymer ratio (X1), Concentration of surfactant (X2) 
and Stirring speed (RPM) (X3) at two levels low and high 
were selected and response surface plots were generated. 
The microsponges were prepared by Quassi-emulsion 
solvent diffusion method. Various characterizations that 
were carried out include entrapment efficiency, percentage 
yield, particle size determination, in-vitro drug release 
studies and kinetic modeling of drug release. Statistical 
analyses of batches and surface response studies were done 
to understand the effect of various independent variables on 
the dependent variables.  Lastly it was concluded that 
microsponges of Acyclovir using QbD approach were 
successfully developed. 
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